Actualising the power of antibody-drug conjugates as cancer therapeutics
European Pharmaceutical Review
AUGUST 24, 2022
tag ® , inspired by the unique features of microtubule biology and perfectly suited for DAR 2 and DAR 4 ADCs. Modi S, Saura C, Yamashita T, et al. 5 Thus, the antibody is able to protect the payload from unwanted interactions with circulating proteins and cells. Tubulis’ second technology platform is called Tub?tag
82 
Let's personalize your content